Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.76 |
| ▸ | KDR | P35968 | 12/20 | 0.76 |
| ▸ | CSK | P41240 | 1/20 | 0.69 |
| ▸ | TEK | Q02763 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.64 |
| ▸ | FLT4 | P35916 | 2/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | CIT | O14578 | 1/20 | 0.64 |
| ▸ | GAK | O14976 | 1/20 | 0.64 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.64 |
| ▸ | STK17B | O94768 | 1/20 | 0.64 |
| ▸ | STK10 | O94804 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448777 | 0.93 | KDR (0.66) | SRCKDRCSKTEKEGFR | |
| SCHEMBL6055771 | 0.86 | SRC (1.00) | SRCKDRCSKTEKEGFR | |
| SCHEMBL3679536 | 0.85 | SRC (1.00) | SRCKDRCSKTEKEGFR | |
| SCHEMBL3743570 | 0.81 | KDR (1.00) | SRCKDREGFRFLT4FGFR1 | |
| SCHEMBL6906281 | 0.80 | EGFR (0.86) | SRCKDREGFREPHB4FLT4 | |
| SCHEMBL5958954 | 0.80 | RET (0.72) | SRCKDRCSKTEKEGFR | |
| SCHEMBL3673614 | 0.80 | KDR (0.88) | SRCKDRCSKTEKEGFR | |
| SCHEMBL27957018 | 0.80 | EGFR (0.88) | SRCKDREGFREPHB4FLT4 | |
| SCHEMBL15591842 | 0.79 | EGFR (0.89) | SRCKDREGFREPHB4FLT4 | |
| SCHEMBL28350781 | 0.79 | EGFR (0.76) | SRCKDRCSKTEKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065018-A1 | Preparation and use of heterogeneous catalyst components for olefins polymerization | (1) REPSOL QUIMICA S.A. | 2005-03-24 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| EP-0953580-B1 | Preparation and use of heterogeneous catalyst components for olefins polymerization | REPSOL QUIMICA SA (ES) | 2004-04-14 | — | — | EP | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| US-20030144135-A1 | PREPARATION AND USE OF HETEROGENEOUS CATALYST COMPONENTS FOR OLEFINS POLYMERIZATION | REPSOL QUIMICA S.A. (ES) | 2003-07-31 | — | — | US | disclosed |
| EP-1326859-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| EP-0955306-B1 | Functionalized metallocene compounds, synthesis process and use thereof | REPSOL QUIMICA SA (ES) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| US-6114555-A | Functionalized metallocene compounds, synthesis process and use thereof | REPSOL QUIMICA S.A. (ES) | 2000-09-05 | — | — | US | disclosed |
| EP-0955306-A1 | Functionalized metallocene compounds, synthesis process and use thereof | REPSOL QUIMICA S.A. (ES) | 1999-11-10 | — | — | EP | disclosed |
| EP-0953580-A1 | Preparation and use of heterogeneous catalyst components for olefins polymerization | REPSOL QUIMICA S.A. (ES) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | SRC 2823/4885KDR 2192/4885CSK 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.